Pharmabiz40m
Mainstay Medical Holdings announces outcomes from RESTORE clinical trial of ReActiv8 to treat intractable chronic low back pain
Mainstay Medical Holdings announces outcomes from RESTORE clinical trial of ReActiv8 to treat intractable chronic low back pain: Dublin, Ireland Saturday, January 18, 2025, 18:00 ...
Pharmabiz1h
NIH-funded study finds contact lenses used to slow nearsightedness in youth have a lasting effect
Bethesda, Maryland Saturday, January 18, 2025, 17:00 Hrs [IST] ...
Pharmabiz2h
UCB’s 320 mg/2 mL prefilled syringe and autoinjector for single-injection administration option is available now in US
UCB’s 320 mg/2 mL prefilled syringe and autoinjector for single-injection administration option is available now in US: Brussels, Belgium Saturday, January 18, 2025, 16:00 Hrs [ ...
Pharmabiz2h
Glenmark Life Sciences rebrands as Alivus Life Sciences
Glenmark Life Sciences, a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas, announces its change of ...
Pharmabiz3h
Caris Life Sciences collaborates with Ontada to advance oncology research and the adoption of precision medicine
Caris Life Sciences collaborates with Ontada to advance oncology research and the adoption of precision medicine: Irving, Texas Saturday, January 18, 2025, 15:00 Hrs [IST] Caris L ...
Pharmabiz4h
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer
UAE health ministry approves Biomerica’s Fortel PSA Screening Test to detect an early sign of prostate cancer: Irvine, California Saturday, January 18, 2025, 14:00 Hrs [IST] Bio ...
Pharmabiz3h
China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer
China NMPA grants marketing authorization to IMPACT Therapeutics’ Senaparib for 1L maintenance therapy in ovarian cancer: Shanghai Saturday, January 18, 2025, 15:30 Hrs [IST] IM ...
Pharmabiz3d
Chugai Pharma to transfer future marketing of anti-cancer agent, Tarceva tablets 25, 100 & 150 in Japan to Cheplapharm
Chugai Pharmaceutical Co., Ltd. and Cheplapharm K.K. announced that Chugai will transfer the business in Japan concerning the anti-cancer agent Tarceva tablets 25, 100, and 150 to Cheplapharm. Chugai ...
Pharmabiz3d
THE JAN VISHWAS ACT
The Indian Parliament had passed the Jan Vishwas (Amendment of Provisions) Bill, 2023 to remove stringent punishments such as imprisonment from some of the provisions of the Drugs and Cosmetics Act, ...
Pharmabiz2d
Takeda’s flagship GICC to create 750 jobs, foster technological innovation with emphasis on plasma-based therapy
Takeda, a global leader in biopharmaceutical innovation, has inaugurated its flagship Global Innovation Capability Centre (ICC). The Takeda India ICC is a part of Takeda’s Data, Digital & Technology ...
Pharmabiz2d
NIH-funded study finds cases of ME/CFS increase following SARS-CoV-2
New findings from the National Institutes of Health’s (NIH) Researching Covid to Enhance Recovery (RECOVER) Initiative suggest that infection with SARS-CoV-2, the virus that causes Covid-19, may be ...
Pharmabiz2d
Santhera gets positive recommendation from Scottish Medicines Consortium for use of Agamree to treat Duchenne muscular dystrophy
Santhera Pharmaceuticals, a Swiss specialty pharmaceutical company, announces that the Scottish Medicines Consortium (SMC) has published recommendations that Agamree (vamorolone) is accepted for use ...